Crucell N.V.
AMS:CRXL ISIN:NL0000358562
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharma company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. The Company licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.
News
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands, 7 January 2009 - Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today confirms that it is in friendly discussions with Wyeth that may lead to a combination of the two companies. These discussions are at a preliminary stage and there is no certainty that they will result in a transaction. An update will be provided in due course.
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands (January 6, 2009) - Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced a non-exclusive STAR® research and commercial license agreement with Pennsylvania-based Centocor, Inc. for the production of monoclonal antibodies. Financial details of the agreement were not disclosed.
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands/Parsippany, USA, 18 December 2008 - DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announced that CSL Limited, a global biopharmaceutical company headquartered in Melbourne, Australia, signed a license agreement allowing CSL to develop protein therapeutics for multiple undisclosed disease targets on the PER.C6® platform. Under the terms of the agreement, CSL is responsible for the development of protein and antibody products resulting from this alliance. Financial terms of the agreement were not disclosed.
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands/Parsippany, USA, 18 December 2008 - DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announced that GlaxoSmithKline (GSK) signed a license agreement allowing GSK to research a recombinant protein on the PER.C6® platform. Financial terms of the agreement were not disclosed.
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands (December 17, 2008) - Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that it has signed a second exclusive, commercial license agreement with North Carolina-based Talecris Biotherapeutics for an undisclosed and specific protein and the exclusive rights to produce that protein using the PER.C6® cell line.
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands, 11 December 2008 - Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that its monoclonal antibody (mAb) directed against a broad range of influenza virus strains has strongly outperformed the most current anti-influenza drug in preclinical tests.
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands, 8 December 2008 - Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announced that the Chinese Authorities have released Hepavax-Gene® for registration and quality control in China.
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands/Parsippany, USA, 25 November 2008 - DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announced that Hungary-based Gedeon Richter Plc. signed a commercial license agreement allowing Gedeon Richter to develop and produce certain biopharmaceuticals on the PER.C6® platform. Other terms of the agreement were not disclosed. About PER.C6® technology Crucell's PER.C6® technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6® technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.
Crucell N.V. (AMS:CRXL) Crucell achieves profitability in Q3 2008. Crucell announces third quarter 2008 results with net income of €12.3 million. Total revenue and other operating income increased by 31% to €82.1 million compared to the same quarter last year. Gross margin in the third quarter mproved to 50% (from 36% last year). 2008 full year guidance for total revenue and other operating income growth increased to 25-30% in constant currencies (from 20%).
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands (November 4, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that it will release its financial results for the third quarter of 2008 on Tuesday, November 11, 2008 at 07:45 Central European Time (CET).
###
3,609 COMPANY PROFILE VIEWS
- Diese Seite wurde besucht: (letzten 7 Tagen: 11) (letzten 30 Tagen: 60) (seit Veröffentlichung: 3588)
